Continue
By using our website you accept our cookies policy.Find out more

2019 CRACK IT challenges: Transgene Track

Funding details
Registration opens
12 Sep 2019, 09:56
Registration closes
06 Nov 2019, 00:00
Closes
06 Nov 2019, 00:00
Award
Up to £100k in Phase 1, up to £1m in Phase 2.
Organisation
NC3Rs
Summary

Overall aim

The aim of this Challenge is to develop a non-invasive imaging approach to determine the in vivoefficacy and biodistribution of (chimeric antigen receptor) CAR-T cells and adeno-associated viruses (AAVs).

 

Duration

Phase 1: six months, Phase 2: Up to three years

 

Budget

Phase 1: Up to £100k, Phase 2: Up to £1 million

 

Sponsor(s)

GSK and Novartis

 

Background

Cell and gene therapies are emerging treatment modalities that offer new possibilities for the treatment of previously incurable conditions. They can be broadly categorised into two subsets: in vivo gene therapy, which involves the introduction of a therapeutic vector directly into the patient andex vivo gene therapy, which primarily uses haematopoietic cells to carry the transgenes of interest.

 

For more information, click here.

Related Funding Opportunities